Friday - May 9, 2025

LOGIN  |  REGISTER
Viking Therapeutics
Astria Therapeutics

Encompass Health announces date of 2024 first quarter earnings call

April 10, 2024 | Last Trade: US$115.91 1.57 -1.34

BIRMINGHAM, Ala., April 10, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its first quarter ended March 31, 2024, after the market closes Wednesday, April 24, 2024. The Company will host an investor conference call at 10 a.m. ET on April 25, 2024, to discuss its results.

The conference call may be accessed by dialing 800-579-2543 and giving the conference ID EHCQ124. International callers should dial 785-424-1699 and give the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.

A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Media contact:
Kennedi Spurling | 205-970-5912
kennedi.spurling@encompasshealth.com

Investor Relations contact:
Mark Miller | 205-970-5860
mark.miller@encompasshealth.com

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page